Scinopharm Taiwan, Ltd.

Scinopharm Singapore Pte Ltd.

Scniopharm Singapore Pte Ltd.

Tsung-Yu Hsiao

Yuan-Xiu Liao

Jyh-Hsiung Liao

Ming-Chih Wu

Meng-Fen Ho

Shu-Ping Chen

Yung-Hung Chang

Chia-Ning Lin

Yu-Li Lin

Julian Paul Henschke

Wei-Yu Chen

George Schloemer

YuanChang Huang

Wei-Shuo Lo

Ping-Yu Wu

MengFen Ho

Hsin-Che Huang

Chen-Wei Lin

HsinChang Tseng

Chi-Nung Hsiao

WenShing Tsao

Hsin-Chang Tseng

Yu-Hui Huang

The present invention provides improved processes for purifying semaglutide or liraglutide. Semaglutide or liraglutide is purified via two sequential RP-HPLC purifications followed by a salt-exchange step, where a pH is kept constant in the first and second purification steps. In particular, the processes utilize a halogenated solvent in a sample preparation step, which provides better solubility and an environment suitable for decarboxylation for crude semaglutide or liraglutide prior to a RP-HPLC purification.

Process for purifying semaglutide and liraglutide

The present invention provides improved processes for purifying liraglutide. Liraglutide is purified via two sequential RP-HPLC purifications followed by a salt-exchange step, where a pH is kept constant in the first and second purification steps. In particular, the processes utilize a halogenated solvent in a sample preparation step, which provides better solubility and an environment suitable for decarboxylation for crude liraglutide prior to a RP-HPLC purification.

Process for purifying liraglutide

The present invention provides improved processes for the preparation of elagolix and intermediates thereof. The intermediate of formula VII is achieved by a coupling reaction of a compound of formula V and a N-benzylidene protected compound of formula IV: The present invention is suitable for a large-scale production, avoiding the use of potential genotoxic substances and can be performed under mild conditions.

Process for preparing elagolix sodium and intermediates thereof

The present disclosure provides efficient, economical, and improved processes for synthesizing lifitegrast and intermediates thereof. The currently discloses processes provide a direct synthetic route, avoiding protection or deprotection steps. The currently disclosed process also provides processes for synthesizing lifitegrast using a reduced number of synthetic steps.

Process for preparing lifitegrast and intermediates thereof

The present invention provides processes for the preparation of ataluren. Intermediates for preparing ataluren are also provided.

Process for preparing ataluren and its intermediates

A process for making ixazomib citrate of formula VI comprising reacting a compound of formula V with citric acid to form ixazomib citrate of formula VI: 

Process for preparing ixazomib citrate and intermediates therefor

Provided herein are novel processes and methods for making 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olaparib) and intermediates thereof. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor useful in the treatment of cancers. Benefits of the present disclosure include the use of less toxic compounds and improved yields.

Processes for preparing olaparib

The present invention provides processes for preparing SGLT2 inhibitors, such as dapagliflozin and empagliflozin.

Process for preparing SGLT2 inhibitors and intermediates thereof

The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.

Process for preparing ibrutinib and its intermediates

The present invention provides processes (e.g., arylation reaction) for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors. A representative process of the present application includes the preparation of the compound of formula IV starting from a compound of the formula II with a metalated aryl compound, as disclosed below: 

Process for the preparation of &#x3b2;-C-aryl glucosides

New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.

Crystalline forms of docetaxel and process for preparation thereof

A process of making a polylpeptide or a pharmaceutically acceptable salt thereof comprises reacting a L-lysine protected polypeptide, which comprises L-alanine, L-tyrosine, L-glutamate, and L-lysine that is protected with a protecting group, with a tetraalkylammonium hydroxide in water to remove the protecting group.

Synthesis of glatiramer acetate

Anbydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.

The present invention provides for an efficient method of effecting the resolution of a narwedine amide, and the synthesis of galantamine.

Growing community of inventors

Tainan, Taiwan

Tsung-Yu Hsiao